stars 1 stars 2 stars 3

At Kallyope, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine. Our late-stage pipeline focuses on delivering an effective, easy to use, first-in-class medication. Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. Elismetrep, our lead asset being developed for the acute treatment of migraine, is in Phase 3.

Kallyope Questions

The Kallyope annual revenue was $15.1 million in 2026.

Jay Galeota is the President and Chief Executive Officer of Kallyope.

49 people are employed at Kallyope.

Kallyope is based in New York, New York.

The NAICS codes for Kallyope are [54, 54171, 5417, 541713, 541].

The SIC codes for Kallyope are [873, 87].

Top Kallyope Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users